Financiamento público ao sistema setorial de inovação farmacêutico brasileiro

Detalhes bibliográficos
Ano de defesa: 2015
Autor(a) principal: Luiza Pinheiro Alves da Silva
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Dissertação
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de Minas Gerais
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Biofarmácia
Link de acesso: https://hdl.handle.net/1843/BUBD-A6LPCD
Resumo: The objective of this paper is to present the Brazilian sectoral system of pharmaceutical innovation, with emphasis on the subsystem of public financing and the innovative efforts of pharmaceutical companies. Such system is presented, through the description of the pharmaceutical innovation process and a detailed description of each of its actors and their role is given. An analysis of the public financing for the Brazilian pharmaceutical innovation system is made, from an overview of the instruments used for investment in this sector, in addition to the allocation of resources for pharmaceutical innovation system. It is also analyzed the alignment between actions that encourage development of innovative technologies and the incorporation of such technologies in the Brazilian public health system. Finally, it is shown the innovative efforts of the Brazilian pharmaceutical companies, by analyzing the results of the Innovation Survey (PINTEC) of IBGE and a comparative analysis of the patenting activity of some companies that received some form of federal government funding. The conclusion is that the information available about the public financing instruments for innovation is unclear and scattered. Historically, the health area has received public resources for investment in innovation. It is observed that Brazilian companies mainly perform incremental innovations in the country. This reflects the adoption of a cautious innovation strategy that, although it has been very important to ensure the success of these companies in the significant market for generic drugs, is not enough to bring them closer to the forefront of the technological frontier in this industry. Nonetheless, it is important to note through a change in the allocation of expenditures in R,D & I of the Brazilian pharmaceutical firms a move towards more advanced innovative activities.
id UFMG_cf82a0446f12cd836d2e41bd7e02ebf1
oai_identifier_str oai:repositorio.ufmg.br:1843/BUBD-A6LPCD
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling 2019-08-12T17:03:49Z2025-09-08T23:51:35Z2019-08-12T17:03:49Z2015-05-25https://hdl.handle.net/1843/BUBD-A6LPCDThe objective of this paper is to present the Brazilian sectoral system of pharmaceutical innovation, with emphasis on the subsystem of public financing and the innovative efforts of pharmaceutical companies. Such system is presented, through the description of the pharmaceutical innovation process and a detailed description of each of its actors and their role is given. An analysis of the public financing for the Brazilian pharmaceutical innovation system is made, from an overview of the instruments used for investment in this sector, in addition to the allocation of resources for pharmaceutical innovation system. It is also analyzed the alignment between actions that encourage development of innovative technologies and the incorporation of such technologies in the Brazilian public health system. Finally, it is shown the innovative efforts of the Brazilian pharmaceutical companies, by analyzing the results of the Innovation Survey (PINTEC) of IBGE and a comparative analysis of the patenting activity of some companies that received some form of federal government funding. The conclusion is that the information available about the public financing instruments for innovation is unclear and scattered. Historically, the health area has received public resources for investment in innovation. It is observed that Brazilian companies mainly perform incremental innovations in the country. This reflects the adoption of a cautious innovation strategy that, although it has been very important to ensure the success of these companies in the significant market for generic drugs, is not enough to bring them closer to the forefront of the technological frontier in this industry. Nonetheless, it is important to note through a change in the allocation of expenditures in R,D & I of the Brazilian pharmaceutical firms a move towards more advanced innovative activities.Universidade Federal de Minas GeraisIndústria farmacêuticaInovaçãoFinanciamentoBiofarmáciaFinanciamento público ao sistema setorial de inovação farmacêutico brasileiroinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisLuiza Pinheiro Alves da Silvainfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMGMarcia Siqueira RapiniFrancisco Horacio Pereira de OliveiraThiago Caliari SilvaO objetivo deste trabalho é apresentar o sistema setorial de inovação farmacêutico brasileiro, com ênfase no subsistema de financiamento público e no esforço inovativo das empresas farmacêuticas. Caracteriza-se esse sistema, apresentando o processo de inovação farmacêutico, e também descrições detalhadas de cada um de seus atores e seu papel. É feita uma análise de como são realizados os financiamentos públicos no sistema de inovação farmacêutico brasileiro, a partir de um panorama geral dos instrumentos utilizados para investimento no setor, além da alocação dos recursos para o sistema de inovação farmacêutico. É realizada ainda uma análise do alinhamento entre as ações de estímulo ao desenvolvimento de tecnologias inovadoras e a incorporação de novas tecnologias no SUS. Por fim, é mostrado o esforço inovador das empresas farmacêuticas, por meio da análise dos resultados da Pesquisa de Inovação (PINTEC) do IBGE e uma análise comparada da atividade de patenteamento de algumas empresas que receberam fomento do governo federal. Conclui-se que as informações disponíveis a respeito dos instrumentos de financiamento público a inovação são pouco claras e dispersas. Historicamente a área da saúde tem recebido recursos públicos para investimento em inovação. Observa-se que as empresas brasileiras realizam prioritariamente inovações incrementais no país. Isto indica a adoção de uma estratégia de inovação pouco ousada que, apesar de ter sido muito importante para garantir o sucesso destas empresas no mercado expressivo dos medicamentos genéricos, não é suficiente para aproximá-las da vanguarda da fronteira tecnológica do setor. No entanto, é importante notar, pela mudança na alocação de dispêndios em P,D&I das empresas farmacêuticas brasileiras um movimento em relação a atividades inovativas mais avançadas.UFMGORIGINAL20151215_disserta__o_luiza___ajustada_final.pdfapplication/pdf2822234https://repositorio.ufmg.br//bitstreams/af9a9802-eaac-4291-8bdf-6c6e74c69d46/download4030541da8f1e25538631c72cdf0acc4MD51trueAnonymousREADTEXT20151215_disserta__o_luiza___ajustada_final.pdf.txttext/plain275823https://repositorio.ufmg.br//bitstreams/72fce80a-ce27-46f7-bc0a-4528514a487f/download64b9ae25d43665648e7e0a9d2abbafcbMD52falseAnonymousREAD1843/BUBD-A6LPCD2025-09-08 20:51:35.075open.accessoai:repositorio.ufmg.br:1843/BUBD-A6LPCDhttps://repositorio.ufmg.br/Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2025-09-08T23:51:35Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.none.fl_str_mv Financiamento público ao sistema setorial de inovação farmacêutico brasileiro
title Financiamento público ao sistema setorial de inovação farmacêutico brasileiro
spellingShingle Financiamento público ao sistema setorial de inovação farmacêutico brasileiro
Luiza Pinheiro Alves da Silva
Biofarmácia
Indústria farmacêutica
Inovação
Financiamento
title_short Financiamento público ao sistema setorial de inovação farmacêutico brasileiro
title_full Financiamento público ao sistema setorial de inovação farmacêutico brasileiro
title_fullStr Financiamento público ao sistema setorial de inovação farmacêutico brasileiro
title_full_unstemmed Financiamento público ao sistema setorial de inovação farmacêutico brasileiro
title_sort Financiamento público ao sistema setorial de inovação farmacêutico brasileiro
author Luiza Pinheiro Alves da Silva
author_facet Luiza Pinheiro Alves da Silva
author_role author
dc.contributor.author.fl_str_mv Luiza Pinheiro Alves da Silva
dc.subject.por.fl_str_mv Biofarmácia
topic Biofarmácia
Indústria farmacêutica
Inovação
Financiamento
dc.subject.other.none.fl_str_mv Indústria farmacêutica
Inovação
Financiamento
description The objective of this paper is to present the Brazilian sectoral system of pharmaceutical innovation, with emphasis on the subsystem of public financing and the innovative efforts of pharmaceutical companies. Such system is presented, through the description of the pharmaceutical innovation process and a detailed description of each of its actors and their role is given. An analysis of the public financing for the Brazilian pharmaceutical innovation system is made, from an overview of the instruments used for investment in this sector, in addition to the allocation of resources for pharmaceutical innovation system. It is also analyzed the alignment between actions that encourage development of innovative technologies and the incorporation of such technologies in the Brazilian public health system. Finally, it is shown the innovative efforts of the Brazilian pharmaceutical companies, by analyzing the results of the Innovation Survey (PINTEC) of IBGE and a comparative analysis of the patenting activity of some companies that received some form of federal government funding. The conclusion is that the information available about the public financing instruments for innovation is unclear and scattered. Historically, the health area has received public resources for investment in innovation. It is observed that Brazilian companies mainly perform incremental innovations in the country. This reflects the adoption of a cautious innovation strategy that, although it has been very important to ensure the success of these companies in the significant market for generic drugs, is not enough to bring them closer to the forefront of the technological frontier in this industry. Nonetheless, it is important to note through a change in the allocation of expenditures in R,D & I of the Brazilian pharmaceutical firms a move towards more advanced innovative activities.
publishDate 2015
dc.date.issued.fl_str_mv 2015-05-25
dc.date.accessioned.fl_str_mv 2019-08-12T17:03:49Z
2025-09-08T23:51:35Z
dc.date.available.fl_str_mv 2019-08-12T17:03:49Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/1843/BUBD-A6LPCD
url https://hdl.handle.net/1843/BUBD-A6LPCD
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
bitstream.url.fl_str_mv https://repositorio.ufmg.br//bitstreams/af9a9802-eaac-4291-8bdf-6c6e74c69d46/download
https://repositorio.ufmg.br//bitstreams/72fce80a-ce27-46f7-bc0a-4528514a487f/download
bitstream.checksum.fl_str_mv 4030541da8f1e25538631c72cdf0acc4
64b9ae25d43665648e7e0a9d2abbafcb
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv repositorio@ufmg.br
_version_ 1862106050189066240

Registros relacionados